Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aldesleukin + zoledronic acid (CHU de Nantes)
- Development stage
- Phase 1
- Lead developer
- CHU de Nantes
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
Aldesleukin + zoledronic acid is an investigational combination therapy being evaluated by Nantes University Hospital for the treatment of hematologic neoplasms, specifically to prevent relapse following haploidentical allogeneic stem cell transplantation (haplo-SCT). Aldesleukin is a recombinant form of interleukin-2 (IL-2) that stimulates the immune system by activating T cells and natural killer (NK) cells through the IL-2 receptor. Zoledronic acid is a bisphosphonate that, in this context, is used to promote the expansion of Vγ9Vδ2 T cells, a subset of gamma-delta T cells with potent anti-tumor cytotoxicity. The combination aims to leverage the synergistic effects of IL-2-mediated immune activation and aminobisphosphonate-induced T cell expansion to enhance the graft-versus-leukemia effect and reduce the risk of disease recurrence.
- Other names
- IL-2 + zoledronic acidinterleukin-2 + zoledronic acidaldesleukin + zoledronate
02
Targets
FDPS (Farnesyl pyrophosphate synthase)GGPPS1 (Geranylgeranyl pyrophosphate synthase)IL-2R (Interleukin-2/interleukin-15 receptor complex)RANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)
Beyond the preview
Go deeper on aldesleukin + zoledronic acid (CHU de Nantes).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aldesleukin + zoledronic acid (CHU de Nantes).